EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Acinetobacter baumannii Complex Infections: New Treatment Options in the Antibiotic Pipeline

Noayna Arshad, Wael Azzam, Marya D Zilberberg, Andrew F Shorr iD

Microorganisms · 07.02.2025 · 13 (2) · 356

DOI: 10.3390/microorganisms13020356 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Microorganisms, online erschienen am 07.02.2025. Verfasst von Noayna Arshad und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Medstar Washington Hospital Center, Washington, DC 20010, USA. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acinetobacter baumannii complex (ABC) can result in a panoply of severe syndromes, including pneumonia and septic shock. Options available for treating infections caused by ABC and, more importantly, by carbapenem-resistant ABC (CRAB) are limited because of the increasing prevalence of antimicrobial resistance. Furthermore, many older agents, such as polymyxin and colistin, have limited lung penetration and are associated with significant toxicities. These factors underscore the urgent need for new paradigms to address ABC and CRAB. Two agents, cefiderocol and sulbactam-durlobactam, are now available to treat CRAB infections. In addition, several anti-infectives that target CRAB are in later-stage clinical trials. In order to place these newer molecules in context and to help clinicians appreciate the emerging potential drug development pipeline, we describe the in vitro activity, mechanisms of action, and clinical trial data not only for the commercially now available alternatives, such as cefiderocol and sulbactam-durlobactam, but also review these topics for molecules undergoing phase II and III clinical trials. Specifically, we discuss and analyze data related to four novel drugs from ABC: BV-100, cefepime-zidebactam, zosurabalpin, and OMN6.

Schlagwörter

Stichwörter der Autor:innen

Acinetobacter baumanniantibioticsdevelopmentinfectionpneumonia

Autor:innen und Institutionen

  • Department of Medicine, Medstar Washington Hospital Center, Washington, DC 20010, USA.
  • EviMed Research Group, LLC, Goshen, MA 01032, USA.
  • Pulmonary and Critical Care Medicine, Medstar Washington Hospital Center, Washington, DC 20010, USA.

ORCID-Profile: Andrew F Shorr

Zitieren

APA

Arshad, N., Azzam, W., Zilberberg, M. D., & Shorr, A. F. (2025). Acinetobacter baumannii Complex Infections: New Treatment Options in the Antibiotic Pipeline. Microorganisms, 13(2), 356. https://doi.org/10.3390/microorganisms13020356

Vancouver

Arshad N, Azzam W, Zilberberg MD, Shorr AF. Acinetobacter baumannii Complex Infections: New Treatment Options in the Antibiotic Pipeline. Microorganisms. 2025;13(2):356. doi:10.3390/microorganisms13020356

BibTeX
@article{Arshad2025,
  author = {Arshad, Noayna and Azzam, Wael and Zilberberg, Marya D and Shorr, Andrew F},
  title = {Acinetobacter baumannii Complex Infections: New Treatment Options in the Antibiotic Pipeline},
  journal = {Microorganisms},
  year = {2025},
  volume = {13},
  number = {2},
  pages = {356},
  doi = {10.3390/microorganisms13020356}
}
Kostenlos starten →